Figure 1.
Effect of omalizumab on peripheral blood eosinophil counts
Peripheral blood absolute eosinophil counts were determined at baseline (week 0) and every 2 weeks thereafter for the duration of the study. The actual values for each time point (A), as well as the value as a percentage of the pre-omalizumab baseline (B) are shown.